0001062993-23-002309.txt : 20230206
0001062993-23-002309.hdr.sgml : 20230206
20230206185032
ACCESSION NUMBER: 0001062993-23-002309
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230202
FILED AS OF DATE: 20230206
DATE AS OF CHANGE: 20230206
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Borges Luis
CENTRAL INDEX KEY: 0001684015
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40498
FILM NUMBER: 23592104
MAIL ADDRESS:
STREET 1: TWO CORPORATE DRIVE
STREET 2: C/O FIVE PRIME THERAPEUTICS, INC.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Century Therapeutics, Inc.
CENTRAL INDEX KEY: 0001850119
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 842040295
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3675 MARKET STREET
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
BUSINESS PHONE: 215-981-4000
MAIL ADDRESS:
STREET 1: 3675 MARKET STREET
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0306
4
2023-02-02
0001850119
Century Therapeutics, Inc.
IPSC
0001684015
Borges Luis
3675 MARKET STREET
PHILADELPHIA
PA
19104
0
1
0
0
Chief Scientific Officer
Common Stock
2023-02-02
4
A
0
21875
0
A
21875
D
Common Stock
2023-02-02
4
A
0
21875
0
A
43750
D
Stock Option (right to buy)
4.64
2023-02-02
4
A
0
131250
0
A
2033-02-02
Common Stock
131250
131250
D
Stock Option (right to buy)
4.64
2023-02-02
4
A
0
131250
0
A
2033-02-02
Common Stock
131250
131250
D
Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutic, Inc.'s (the "Company's") common stock. The RSUs vest 25% on February 2, 2024 and the remaining 75% vest on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock.
The option vests 25% on February 2, 2024, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer.
/s/ Michael Diem, Attorney-in-Fact
2023-02-06